Trade Apellis Pharmaceuticals, Inc. - APLS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 24.08 |
| Open | 24.01 |
| 1-Year Change | -46.59% |
| Day's Range | 23.97 - 24.47 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 21, 2025 | 24.07 | 0.22 | 0.92% | 23.85 | 24.51 | 23.85 |
| Mar 20, 2025 | 24.08 | -0.39 | -1.59% | 24.47 | 25.07 | 24.06 |
| Mar 19, 2025 | 24.74 | 0.29 | 1.19% | 24.45 | 25.27 | 24.10 |
| Mar 18, 2025 | 24.35 | -0.10 | -0.41% | 24.45 | 24.94 | 24.06 |
| Mar 17, 2025 | 25.05 | 0.44 | 1.79% | 24.61 | 25.28 | 24.37 |
| Mar 14, 2025 | 24.60 | 0.39 | 1.61% | 24.21 | 24.76 | 24.06 |
| Mar 13, 2025 | 24.29 | -0.26 | -1.06% | 24.55 | 25.18 | 24.20 |
| Mar 12, 2025 | 25.13 | -0.37 | -1.45% | 25.50 | 25.87 | 25.02 |
| Mar 11, 2025 | 25.47 | 0.41 | 1.64% | 25.06 | 25.61 | 24.69 |
| Mar 10, 2025 | 25.06 | 0.11 | 0.44% | 24.95 | 25.15 | 24.42 |
| Mar 7, 2025 | 25.01 | 0.16 | 0.64% | 24.85 | 25.43 | 24.37 |
| Mar 6, 2025 | 25.26 | -0.02 | -0.08% | 25.28 | 25.86 | 24.99 |
| Mar 5, 2025 | 25.94 | 0.79 | 3.14% | 25.15 | 26.06 | 24.70 |
| Mar 4, 2025 | 24.97 | 0.96 | 4.00% | 24.01 | 25.50 | 23.72 |
| Mar 3, 2025 | 24.03 | -0.67 | -2.71% | 24.70 | 24.99 | 23.76 |
| Feb 28, 2025 | 25.05 | -0.80 | -3.09% | 25.85 | 25.85 | 24.24 |
| Feb 27, 2025 | 25.96 | -0.25 | -0.95% | 26.21 | 27.43 | 25.94 |
| Feb 26, 2025 | 26.29 | -0.57 | -2.12% | 26.86 | 28.02 | 26.21 |
| Feb 25, 2025 | 26.84 | -0.61 | -2.22% | 27.45 | 27.45 | 26.53 |
| Feb 24, 2025 | 27.34 | -0.06 | -0.22% | 27.40 | 27.60 | 26.87 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam''s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.| Industry: | Biopharmaceuticals |
100 Fifth Avenue
WALTHAM
MASSACHUSETTS 02451
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 700,000+ traders worldwide that chose to trade with Capital.com